North America Enzyme Replacement Therapy Market
Historic Data:    |   Base Year: 2023   |   Forecast Period: 2024-2031
Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Enzyme Type (Alglucosidase Alfa, Agalsidase Beta, Imiglucerase, Idursulfase, Galsulfase, Velaglucerase Alfa, and Other Enzymes), Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, MPS, Pompe's Disease, SCID, and Other Therapeutic Conditions), Route of Administration (Parenteral and Oral), and End User (Hospitals, Infusion Centers, and Others)

No. of Pages: 162    |    Report Code: BMIRE00027296    |    Category: Life Sciences

Available Report Formats

pdf-format excel-format pptx-format
Request Free Sample Buy Now
North America Enzyme Replacement Therapy Market
Free Sample Buy Now

1. Introduction

1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights
2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research
3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:

4. North America Enzyme Replacement Therapy Market Landscape

4.1 Market Overview
4.2 Porter's Five Forces Analysis
  • 4.2.1 Bargaining Power of Suppliers
  • 4.2.2 Bargaining Power of Buyers
  • 4.2.3 Threat of New Entrants
  • 4.2.4 Competitive Rivalry
  • 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
  • 4.3.1 Raw Material Suppliers
  • 4.3.2 Manufacturers
  • 4.3.3 Distributors/Suppliers
  • 4.3.4 End Users

5. North America Enzyme Replacement Therapy Market – Key Market Dynamics

5.1 Growth Drivers
  • 5.1.1
  • 5.1.2 Increasing prevalence of lysosomal storage disorders (LSDs)
  • 5.1.3 Advancements in recombinant DNA technology
  • 5.1.4 Rising healthcare expenditure
  • 5.1.5 Growing geriatric population
  • 5.1.6 Launch of novel therapies
  • 5.1.7 Favorable reimbursement scenarios
  • 5.1.8 Increasing awareness about LSDs and their treatment options
5.2 Market Opportunities
  • 5.2.1
  • 5.2.2 Increasing pipeline of novel enzyme replacement therapies
  • 5.2.3 Expanding geographic reach
  • 5.2.4 Strategic collaborations and partnerships
  • 5.2.5 Rising demand for personalized medicine
  • 5.2.6 Growing focus on orphan diseases
5.3 Future Trends
  • 5.3.1
  • 5.3.2 Advancement in gene therapy and CRISPR-Cas9 technology
  • 5.3.3 Development of combination therapies
  • 5.3.4 Increased focus on patient-centric care
  • 5.3.5 Rising demand for biosimilars and generic enzyme replacement therapies
  • 5.3.6 Growing importance of real-world evidence and patient registries
5.4 Impact of Drivers and Restraints

6. North America Enzyme Replacement Therapy Market Regional Analysis

6.1 North America Enzyme Replacement Therapy Market Overview
6.2 North America Enzyme Replacement Therapy Market Revenue 2020-2028 (US$ Million)
6.3 North America Enzyme Replacement Therapy Market Forecast Analysis

7. North America Enzyme Replacement Therapy Market Analysis – by Enzyme Type

7.1 Alglucosidase Alfa
  • 7.1.1 Overview
  • 7.1.2 Alglucosidase Alfa: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2031 (US$ Million)
7.2 Agalsidase Beta
  • 7.2.1 Overview
  • 7.2.2 Agalsidase Beta: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2031 (US$ Million)
7.3 Imiglucerase
  • 7.3.1 Overview
  • 7.3.2 Imiglucerase: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2031 (US$ Million)
7.4 Idursulfase
  • 7.4.1 Overview
  • 7.4.2 Idursulfase: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2031 (US$ Million)
7.5 Galsulfase
  • 7.5.1 Overview
  • 7.5.2 Galsulfase: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2031 (US$ Million)
7.6 Velaglucerase Alfa
  • 7.6.1 Overview
  • 7.6.2 Velaglucerase Alfa: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2031 (US$ Million)
7.7 Other Enzymes
  • 7.7.1 Overview
  • 7.7.2 Other Enzymes: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2031 (US$ Million)

8. North America Enzyme Replacement Therapy Market Analysis – by Therapeutic Conditions

8.1 Gaucher's Disease
  • 8.1.1 Overview
  • 8.1.2 Gaucher's Disease: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
8.2 Fabry's Disease
  • 8.2.1 Overview
  • 8.2.2 Fabry's Disease: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
8.3 MPS
  • 8.3.1 Overview
  • 8.3.2 MPS: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Pompe's Disease
  • 8.4.1 Overview
  • 8.4.2 Pompe's Disease: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
8.5 SCID
  • 8.5.1 Overview
  • 8.5.2 SCID: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Other Therapeutic Conditions
  • 8.6.1 Overview
  • 8.6.2 Other Therapeutic Conditions: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

9. North America Enzyme Replacement Therapy Market Analysis – by Route of Administration

9.1 Parenteral
  • 9.1.1 Overview
  • 9.1.2 Other Therapeutic Conditions: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
9.2 Oral
  • 9.2.1 Overview
  • 9.2.2 Other Therapeutic Conditions: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)

10. North America Enzyme Replacement Therapy Market – North America Analysis

10.1 North America
  • 10.1.1 North America Enzyme Replacement Therapy Market Breakdown, by Key Country, 2023 and 2028 (%)
  • 10.1.1.1 North America Enzyme Replacement Therapy Market – Revenue and Forecast Analysis – by Country
  • 10.1.1.1 US: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.1.1 US: North America Enzyme Replacement Therapy Market Breakdown, by Enzyme Type
    • 10.1.1.1.2 US: North America Enzyme Replacement Therapy Market Breakdown, by Therapeutic Conditions
    • 10.1.1.1.3 US: North America Enzyme Replacement Therapy Market Breakdown, by Route of Administration
  • 10.1.1.2 Canada: North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.2.1 Canada: North America Enzyme Replacement Therapy Market Breakdown, by Enzyme Type
    • 10.1.1.2.2 Canada: North America Enzyme Replacement Therapy Market Breakdown, by Therapeutic Conditions
    • 10.1.1.2.3 Canada: North America Enzyme Replacement Therapy Market Breakdown, by Route of Administration
  • 10.1.1.3 Mexico : North America Enzyme Replacement Therapy Market – Revenue and Forecast to 2028 (US$ Million)
    • 10.1.1.3.1 Mexico : North America Enzyme Replacement Therapy Market Breakdown, by Enzyme Type
    • 10.1.1.3.2 Mexico : North America Enzyme Replacement Therapy Market Breakdown, by Therapeutic Conditions
    • 10.1.1.3.3 Mexico : North America Enzyme Replacement Therapy Market Breakdown, by Route of Administration

11. Competitive Landscape

11.1 Heat Map Analysis
11.2 Company Positioning and Concentration

12. North America Enzyme Replacement Therapy Market Industry Landscape

12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Sanofi.
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
13.2 BioMarine Pharmaceutical Inc.
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
13.3 Takeda Pharmaceutical Company Limited.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
13.4 AbbVie Inc.
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
13.5 Janssen Pharmaceutical ( Johnson & Johnson Services,Inc.).
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
13.6 Alexion Pharmaceutical, Inc.(AstaZeneca).
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
  • 13.6.6 Key Developments
13.7 Amicus Therapeutics.
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
13.8 Recordati S.p.A.
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
13.9 CHIESI farmaceutici S.p.A.
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
13.10 Pfizer Inc.
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights

The List of Companies - North America Enzyme Replacement Therapy Market

  1. Sanofi.
  2. BioMarine Pharmaceutical Inc.
  3. Takeda Pharmaceutical Company Limited.
  4. AbbVie Inc.
  5. Janssen Pharmaceutical ( Johnson & Johnson Services,Inc.).
  6. Alexion Pharmaceutical, Inc.(AstaZeneca).
  7. Amicus Therapeutics.
  8. Recordati S.p.A.
  9. CHIESI farmaceutici S.p.A.
  10. Pfizer Inc.
north-america-enzyme-replacement-therapy-market